College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, PR China.
College of Pharmacy, Jinan University, Guangzhou 510632, PR China; Guangdong Provincial Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou 510632, PR China.
J Ethnopharmacol. 2019 Jan 10;228:188-199. doi: 10.1016/j.jep.2018.08.003. Epub 2018 Sep 6.
ETHNOPHARMACOLOGICAL EVIDENCE: With fast development and high pace life in modern society, autoimmune diseases like inflammatory bowel disease had become increasingly common. Bu-Zhong-Yi-Qi-Tang (BZYQT), a famous traditional Chinese medicine prescription (TCMP), has been used for 700 years mainly in Eastern Asia countries for the treatment of gastrointestinal and respiratory disorder, and weakness after serious diseases. These diseases were proved to be closely related to human immune system, among which, mucosal immune system is the largest immune system. So it is necessary to discover the mucosal immune related bioactive components of BZYQT. AIM OF THE STUDY: To evaluate the mucosal immunomodulatory bioactivity of BZYQT and ingredients. MATERIALS AND METHODS: Peyer's patches were collected from mice administrated orally with BZYQT, its related Octadecylsilane (ODS) fractions and polysaccharide part. Productions of several cytokines including IL-2, IL-4, IL-5, and IFN-γ from T lymphocytes were tested with enzyme linked immunosorbent assay (ELISA) by Peyer's patch cells ex vivo experiments. Chemical profile including low molecular part and polysaccharide part were investigated. Low molecular part of BZYQT and related ODS fractions were analyzed by ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q/TOF-MS) based on LC-MS information from self-established compound library. exclusion chromatography, and chemical property has been analyzed. RESULT: Three-days' administration of BZYQT enhanced productions of IL-4 and IFN-γ in T lymphocytes of Peyer's patches in addition to IL-2. Some hydrophobic low molecular weight fractions (30%, 70% and 100% MeOH ODS fraction), which were fractionated from BZYQT by ODS column chromatography, showed enhancing or suppressive effects on productions of IL-2, IL-4 or IL-5 in T lymphocytes of Peyer's patches after oral administration. Besides, 161 components from hydrophobic low molecular weight fractions of BZYQT were unequivocally identified or tentatively characterized by UPLC-Q/TOF-MS according to retention time behaviors and fragments, and most of them were flavonoids and saponins from Glycyrrhizae Radix, Citri Reticulatae Pericarpium, and Cimicifugae Rhizoma. Polysaccharide part was separated and purified both by anion-exchange and size. BZYQT also contained at least one neutral and three weakly or strongly acidic polysaccharides, and analysis of their chemical properties indicated that a neutral polysaccharide was glucan, and acidic polysaccharides possessed heteroglycan and pectic arabinogalactan features. Murine administration of polysaccharide fractions of BZYQT induced different changes on functions of T lymphocytes in Peyer's patches from hydrophobic low molecular weight fractions. By experiment using intranasally-immunized mice, BZYQT negatively regulated antibody response in lung as combinatorial actions of its low molecular weight ingredients and polysaccharides. CONCLUSION: BZYQT contains several low and macromolecular weight ingredients, which affect to immune-function of T lymphocytes in Peyer's patches, and the formula expresses its regulative activity on lower respiratory immune system through combinatorial actions of these ingredients on immunocompetent cells in Peyer's patches.
民族药理学证据:随着现代社会的快速发展和快节奏的生活,像炎症性肠病这样的自身免疫性疾病变得越来越常见。补中益气汤(BZYQT)是一种著名的中药方剂(TCMP),主要在东亚国家使用了 700 年,用于治疗胃肠道和呼吸道紊乱以及严重疾病后的虚弱。这些疾病被证明与人体免疫系统密切相关,其中黏膜免疫系统是最大的免疫系统。因此,有必要发现 BZYQT 的黏膜免疫相关的生物活性成分。
研究目的:评估 BZYQT 及其成分的黏膜免疫调节生物活性。
材料与方法:通过口服 BZYQT、相关十八烷基硅烷(ODS)馏分和多糖部分,从接受处理的小鼠的派尔氏斑中收集 T 淋巴细胞。通过派尔氏斑细胞的体外实验,用酶联免疫吸附测定(ELISA)法检测几种细胞因子(IL-2、IL-4、IL-5 和 IFN-γ)的产生。对化学成分(包括低分子部分和多糖部分)进行了研究。通过基于自建立的化合物库的超高效液相色谱-四极杆飞行时间串联质谱(UPLC-Q/TOF-MS)分析 BZYQT 及其相关 ODS 馏分的低分子部分,同时进行排除色谱和化学性质分析。
结果:连续三天口服 BZYQT 可增强派尔氏斑中 T 淋巴细胞的 IL-4 和 IFN-γ的产生,同时也可增强 IL-2 的产生。通过 ODS 柱层析,从 BZYQT 中分离得到的 30%、70%和 100%甲醇 ODS 馏分等一些疏水性低分子量馏分,在口服给药后对 T 淋巴细胞中 IL-2、IL-4 或 IL-5 的产生具有增强或抑制作用。此外,根据保留时间行为和碎片,通过 UPLC-Q/TOF-MS 从 BZYQT 的疏水性低分子量馏分中鉴定出或初步鉴定出 161 个成分,这些成分大部分为甘草、陈皮和升麻中的黄酮类和皂苷。多糖部分通过阴离子交换和大小两种方法进行分离和纯化。BZYQT 还含有至少一种中性和三种弱酸性或强酸性多糖,其化学性质分析表明,中性多糖为葡聚糖,酸性多糖具有杂多糖和果胶阿拉伯半乳聚糖的特征。BZYQT 的多糖部分在体内给药后,可诱导派尔氏斑中 T 淋巴细胞的功能发生不同的变化。通过鼻腔免疫接种的小鼠实验,BZYQT 通过其低分子量成分和多糖的组合作用,对肺部的抗体反应产生负调节作用。
结论:BZYQT 含有几种低分子量和高分子量的成分,这些成分影响派尔氏斑中 T 淋巴细胞的免疫功能,该配方通过这些成分在派尔氏斑中的免疫活性细胞上的组合作用,表达对下呼吸道免疫系统的调节活性。
Arch Pharm Res. 2022-6